NKX2-5 and hepatocellular carcinoma: It has been predicted via bioinformatic analysis and confirmed by chromatin immunoprecipitation analysis that in hepatocellular carcinoma cells the promoter of ERBB2 binds to the transcription factor NKX2-5, resulting in a negative regulatory effect [52].